Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
Search
Nelli Milosch
Nelli Milosch on what makes our people different
Full data chronic kidney disease trial efficacy
Positive full data results announced from the EMPA-KIDNEY Phase III trial in adults with chronic kidney disease
Boehringer Ingelheim Venture Fund invests precision antimicrobials
Boehringer Ingelheim Venture Fund invests in the development of precision antimicrobials
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
The first liquid solution for hypertension in cats
Boehringer Ingelheim launches Semintra® 10 mg/ml Oral Solution in selected European countries for the treatment of feline hypertension.
Winners of the 2020 European PRRS Research Award
Winners of the 2020 European PRRS Research Award announced Three winner awarded 25,000 euro each for their research.
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
AI&Data Science Fellowship Tuebingen
AI&Data Science Fellowship Tuebingen
Advance study vaccinating increased milk production
[New ADVANCE study shows vaccinating with Bovela® results in increased milk production
A lifetime for patients with mental health conditions
Chris Underhill is a social entrepreneur and participant at the Making More Health Convention.
Biotherapeutics Discovery
We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
AUROBAC's Strategy & Pipeline Against Severe Infections & Resistance
AUROBAC THERAPEUTICS presents strategy and growing pipeline to tackle severe infections and antimicrobial resistance
Boehringer Ingelheim becomes member of IPC
Boehringer Ingelheim becomes member of IPC Boehringer Ingelheim is proud to join the International Poultry Council thus reaffirming its strong long-term commitment to shaping the future of poultry health. The International Poultry Council represents a uni
LastMile initiative to address barriers in animal healthcare
The ‘LastMile’ initiative addresses major barriers in animal healthcare sector in Sub-Saharan African
License to develop new fibro-inflammatory disease treatments
License to develop new fibro-inflammatory disease treatments
CAROLINA-CARMELINA-Asia-analysis
CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
FIBRONEER™ Phase III program initiated
FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
TCO patient podcasts
From clinical trials to living with cancer, hear patient perspectives on different cancer topics in this podcast series.
InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Boehringer Ingelheim Access to Healthcare Strategy 2025
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach.
Investment of 65 million euro in avian vaccines in France
Boehringer Ingelheim is set to invest almost €65 million in a high-tech building at its Lyon Portes-des-Alpes site in Saint-Priest, France (Rhône), to meet the growing demand worldwide for avian vaccines
Joint venture to fight Antimicrobial Resistance
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
Saving Stroke Patients around the world
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.